From Uncovered Genomic Elements to a Universal Cancer Vaccine
Presented by
Description
We are at the forefront of developing a novel cancer treatment strategy by identifying human endogenous retroviral (HERV) sequences that reactivate specifically in cancer cells and can be targeted by the immune system. By leveraging comprehensive omics data and cutting-edge AI-assisted analyses, we pinpoint promising targets for innovative cancer therapies. Our approach aims to broaden the scope of patients who can benefit from these treatments on a global scale. Currently, we are in the final stages of preparing for a clinical trial of our first vaccine targeting Triple Negative Breast Cancer, with plans to extend this strategy to additional cancer types.
